BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 210 filers reported holding BRIDGEBIO PHARMA INC in Q4 2021. The put-call ratio across all filers is 0.63 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,406,928 | +1330.6% | 167,119 | +799.5% | 0.03% | +1033.3% |
| Q1 2023 | $308,039 | -68.2% | 18,579 | -80.9% | 0.00% | -62.5% |
| Q3 2022 | $970,000 | -39.7% | 97,519 | -44.9% | 0.01% | -50.0% |
| Q2 2022 | $1,608,000 | -26.7% | 177,026 | -18.2% | 0.02% | -20.0% |
| Q1 2022 | $2,195,000 | -19.2% | 216,300 | +32.8% | 0.02% | -20.0% |
| Q4 2021 | $2,717,000 | +218.5% | 162,900 | +795.1% | 0.02% | +177.8% |
| Q3 2021 | $853,000 | -70.2% | 18,200 | -61.2% | 0.01% | -70.0% |
| Q2 2021 | $2,858,000 | +2.8% | 46,887 | +3.9% | 0.03% | -11.8% |
| Q1 2021 | $2,780,000 | +337.8% | 45,137 | +405.7% | 0.03% | +277.8% |
| Q4 2020 | $635,000 | -28.7% | 8,926 | -62.4% | 0.01% | -47.1% |
| Q3 2020 | $890,000 | +2.1% | 23,741 | -11.1% | 0.02% | +41.7% |
| Q2 2020 | $872,000 | – | 26,692 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 3,835,722 | $103,449,000 | 44.18% |
| Kohlberg Kravis Roberts & Co. L.P. | 36,900,661 | $995,211,000 | 12.26% |
| SC US (TTGP), LTD. | 2,544,738 | $68,632,000 | 4.69% |
| Cormorant Asset Management, LP | 2,780,885 | $75,000,000 | 4.31% |
| Perceptive Advisors | 6,706,268 | $180,868,000 | 4.15% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $717,968,000 | 3.22% |
| Hillhouse Capital Management | 2,035,790 | $54,905,000 | 1.75% |
| Alpine Group USVI, LLC | 20,000 | $539,000 | 1.70% |
| HHLR ADVISORS, LTD. | 2,352,900 | $63,458,000 | 1.42% |
| SCGE MANAGEMENT, L.P. | 588,235 | $15,865,000 | 0.79% |